Overview

• Patients undergoing bariatric surgery lost an average of 58 pounds over two years compared to about 12 pounds for those on GLP-1 medications.
• Up to 70% of GLP-1 patients stop treatment within one year, undermining sustained weight-loss outcomes.
• Real-world weight loss from GLP-1 drugs falls well below the 15 to 21 percent range observed in clinical trials.
• Bariatric surgery patients are 18% less likely to develop psychiatric disorders such as anxiety or substance abuse than those on GLP-1 treatments.
• Approximately 6% of American adults currently use GLP-1 therapies, fueling increased body lift surgeries for excess skin.